top of page

Pre-clinical Data to be Presented at 17th IASLC World Conference on Lung Cancer

Dublin, Ireland, December 6, 2016 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that data on IBL-301, a pan-PIM/pan-PI3K/mTOR inhibitor, will be presented at the 17th IASLC World Conference on Lung Cancer taking place in Vienna, December 4-7, 2016.

The pre-clinical data was generated through a collaboration between Inflection Biosciences and Trinity College Dublin, led by Dr. Kathy Gately, Clinical Lecturer Thoracic Oncology Research at the Institute of Molecular Medicine, St. James’s Hospital Dublin. The collaboration is jointly funded by Enterprise Ireland and Inflection Biosciences Ltd.

Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences commented “This work has shown that PIM is abundantly expressed in tumour samples from lung cancer patients. The data generated through this collaboration is a further validation for the company’s strategy of targeting both PIM kinase and PI3K/mTOR pathways.”

The details for the poster presentations are as follows:

Poster Title: Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC

Date & Time: 2.30 pm – 3.45 pm Wednesday 7th December, 2016

Presenter: Dr. Gillian Moore

ID Number: 4328

Session Track: Biology/Pathology

Location: Hall B (Poster Area)

Poster Title: Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC

Date & Time: 2.30 pm – 3.45 pm Monday 5th December, 2016

Presenter: Dr. Gillian Moore

ID Number: 5355

Session Track: Advanced NSCLC

Location: Hall B (Poster Area)

The full abstracts can be viewed here.

About PIM/PI3 kinase inhibitors

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page